Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 40kWORD 9k
22 January 2020
Question for written answer E-000328/2020
to the Commission
Rule 138
Frédérique Ries (Renew)
 Answer in writing 
 Subject: New Commission proposals to address the shortage of medicinal products in the European Union

In October 2019, Parliament’s Committee on the Environment, Public Health and Food Safety approved the appointment of Ms Kyriakides as European Commissioner for Health. During her hearing, she said she would work with the industry and the Member States to reduce shortages in medicinal products in Europe. This is a very real problem and injurious to the public health goal of guaranteeing access to top quality, affordable medicines for patients.

1. What possible solutions does the Commission have in mind to end these shortfalls in medicine stocks which pose a significant risk to patients’ health?

2. Will the Commission be able, in particular, to resolve those problems that stand in the way of access to essential medicines, such as high price erosion, cumbersome statutory processes in some Member States, and the fact that the manufacture of active pharmaceutical ingredients (APIs) is left to countries outside the EU?

3. Would the Commission be prepared to set up a high-level pharmaceutical forum where the industry, patients, political decision-makers and other stakeholders could come together to define strategic recommendations on how to ensure sustainable access to medicinal products, while at the same time enhancing the competitiveness of the European pharmaceutical industry?

Original language of question: FR
Last updated: 25 September 2020Legal notice - Privacy policy